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Background: This study aimed to better understand the supporting role that mutational profiling (MP) of DNA
from microdissected cytology slides and supernatant specimens may play in the diagnosis of malignancy in fine-needle
aspirates (FNA) and biliary brushing specimens from patients with pancreaticobiliary masses.
Methods: Cytology results were examined in a total of 30 patients with associated surgical (10) or clinical (20)
outcomes. MP of DNA from microdissected cytology slides and from discarded supernatant fluid was analyzed in 26
patients with atypical, negative or indeterminate cytology.
Results: Cytology correctly diagnosed aggressive disease in 4 patients. Cytological diagnoses for the remaining 26
were as follows: 16 negative (9 false negative), 9 atypical, 1 indeterminate. MP correctly determined aggressive disease
in 1 false negative cytology case and confirmed a negative cytology diagnosis in 7 of 7 cases of non-aggressive disease.
Of the 9 atypical cytology cases, MP correctly diagnosed 7 as positive and 1 as negative for aggressive disease. One
specimen that was indeterminate by cytology was correctly diagnosed as non-aggressive by MP. When first line
malignant (positive) cytology results were combined with positive second line MP results, 12/21 cases of aggressive
disease were identified, compared to 4/21 cases identified by positive cytology alone.
Conclusions: When first line cytology results were uncertain (atypical), questionable (negative), or not possible
(non-diagnostic/indeterminate), MP provided additional information regarding the presence of aggressive disease.
When used in conjunction with first line cytology, MP increased detection of aggressive disease without compromising
specificity in patients that were difficult to diagnose by cytology alone.
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Pancreaticobiliary cancer is associated with a 5-year sur-
vival rate of less than 6%, which has not changed signifi-
cantly in the past 30 years [1]. Thus, traditional clinical
strategies in early diagnosis and patient treatment have
not significantly improved patient outcomes. Although
recent advancements in imaging techniques have in-
creased the sensitivity for detecting pancreatic and bil-
iary solid and cystic lesions [2,3], the standard method* Correspondence: saj@redpathip.com
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unless otherwise stated.of diagnosis, cytological evaluation of fine needle aspi-
rates (FNA) and biliary brushing specimens, carries a
high false negative rate and often yields findings that are
inconclusive [4-7].
False negative cytology results are largely due to sam-
pling variability that can result from FNA and biliary
brushing procedures, acellularity of the corresponding
specimens, and difficulty in characterizing cellular atypia
due to the aforementioned reasons. Sites of advanced dis-
ease are inadvertently missed and few to no cells are cap-
tured due to biological variation within the neoplastic cell
population leading to mischaracterization [8,9]. Theseal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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dealing with progressively smaller lesions that are de-
tected earlier with advanced imaging. Collectively, these
limitations make it clear that methods to support and
improve the diagnostic process of pancreaticobiliary can-
cer would greatly enhance the management and care of
patients.
Many studies have highlighted the association be-
tween cumulative DNA damage and pancreaticobiliary
cancers [10-17]. Some studies have also shown that
microdissection-based mutational profiling of DNA can be
clinically useful in diagnosing these malignancies [10-15].
Such molecular analysis is especially significant when mor-
phologic methods are uncertain or not obtainable [18-22].
Like cytology, the use of mutational profiling has tradition-
ally required cellular material that shows morphological
signs of disease in order to extract DNA from microdis-
sected areas of relevant cells. However, pauci- and acellular
specimens at times fail to provide sufficient material for
cell-based DNA mutational profiling.
Recent studies have shown successful mutational profil-
ing of DNA not only from microdissected cytology slides
but also from cell-free supernatant fluid obtained during
preparation of the cytology slides [22]. The supernatant
fractions of FNA and biliary brushing specimens are an
underutilized and often overlooked source of DNA [22,23].
The supernatant of FNA and biliary brushing specimens
is typically discarded but contains DNA that can provide
molecular information even when the cell count is low or
nonexistent [22,23]. The utilization of the cytocentrifu-
gation supernatant can especially be of significant value
in those cases where the cellular material is scarce or
even absent without compromising the material rou-
tinely used for other diagnostic tests. Numerous studies
have reported the utility as well as the high quality of the
extracellular DNA that surrounds cancer cells, with some
studies observing that it may in fact be more representa-
tive of a tumor than intracellular DNA obtained via other
methods [24-32].
We aimed to better understand the supporting role that
mutational profiling of DNA from microdissected cytology
slides and supernatant specimens may play in the accurate
diagnosis of malignancy in patients with pancreaticobili-
ary masses. FNA or biliary brushing procedures were
performed to collect diagnostic specimens. Patients with
associated surgical or clinical follow-up outcomes were
examined by cytopathology as well as mutational profiling
of DNA from microdissected cytology slides and from
supernatant fluid, which is normally otherwise discarded.
More specifically, the study aimed to examine the added
value of mutational profiling for detecting aggressive dis-
ease when first line testing by cytopathology was either
negative or insufficient for diagnosis (i.e. atypical or inde-
terminate) of malignancy.Methods
Study population
This is a retrospective review of patients who presented
with a pancreaticobiliary mass found on cross-sectional
imaging at our institution during a ten month period
from August 2011 to May 2012. All patients underwent
FNA of the pancreaticobiliary mass or biliary brushing if
the FNA was not possible. The Georgetown University
Institutional Review Board granted approval (# Ame1_2011-
553) for review of cytology reports and performance of mu-
tational profiling of FNA and brushing specimens from
patients at Medstar Georgetown University Hospital. The
patient cohort included both cases with unclear cytology
results, such as those with negative, atypical or inde-
terminate (acellular or insufficient cells for cytology diagno-
sis) results, as well as cases with definitive positive cytology
results describing the presence of malignant disease.
Patient outcomes were categorized as “aggressive” based
on either surgical pathology or oncology follow-up report
indications of adenocarcinoma, cholangiocarcinoma, intra-
ductal tubulo-papillary neoplasm, pancreatic cancer treat-
ment, or death from pancreatic cancer. Patient outcomes
were categorized as “non-aggressive” based on at least
3 months of clinical follow-up via cross sectional imaging
or repeat endoscopic ultrasound indicating resolution or
stable (unchanging or shrinking) pancreaticobiliary mass.
Cytology
Pancreaticobiliary mass FNA and biliary brushing speci-
mens were fixed, followed by standard cytology slide prep-
aration. The normally discarded cell-free supernatant fluid
remaining after centrifugation of the cells during cytology
preparation was saved at 4°C for mutational profiling.
Cytology results were categorized as “positive”, “atypical”,
“negative” or “indeterminate” based on language abstracted
from the cytology report. Any case with a cytology report
that clearly noted the presence of adenocarcinoma or ma-
lignancy was defined as “positive” for aggressive disease by
cytology. “Atypical” cytology was defined as any case with
a cytology report listing the presence of atypical cells with
no specific mention as to the presence of adenocarcinoma/
malignancy. “Negative” cytology consisted of any case with
cytology describing the presence of reactive or benign cells
with no specific mention of adenocarcinoma/malignancy
or atypia. Any case lacking a cytology diagnosis due to an
acellular or poorly preserved specimen was defined as hav-
ing “indeterminate” cytology.
The degree of cellularity was also defined for each cy-
tology diagnosis and categorized as “sufficient”, “low”, or
“non-diagnostic” levels. “Sufficient” cellularity was defined
as any case where a cytology diagnosis was made and there
was no mention of a scant or paucicellular sample. “Low”
level cellularity included cases described as having a scant
or paucicellular specimen per the cytology report. “Non-
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nosis could not be made due to a poor quality specimen
per the cytology report.
Mutational profiling of DNA
For mutational profiling, DNA was extracted from cells
microdissected from cytology slides guided by micro-
scopic feature (cellular atypia when present) and from a
portion of each cell-free supernatant sample that is nor-
mally discarded during preparation of cytology specimens.
For the supernatant specimens, DNA was extracted from
5 mL aliquots (Qiagen, Valencia, CA) and then quan-
tified by optical density (NanoDrop, Thermo Scientific,
Wilmington, DE). Microdissected cells from cytology
slides underwent a similar process for DNA extraction
and quantification.
Quantitative PCR was used to establish the amplifiabil-
ity of DNA from each specimen prior to mutational pro-
filing [22]. Specimens that contained sufficient amounts
of amplifiable DNA were categorized as “positive” or
“negative” for aggressive disease based on the presence
or absence, respectively, of at least one mutation in the
form of KRAS point mutation or allelic imbalance (loss of
heterozygosity, LOH) mutation in either the supernatant
fluid DNA or DNA from microdissected cytology slides.
Those with insufficient amounts of amplifiable DNA were
categorized as “non-diagnostic” by mutational profiling.
A clinically validated panel was used for mutational pro-
filing [10-15]. The panel included KRAS oncogene markers
and 16 microsatellite markers (known commercially as
PathFinderTG, PFTG, RedPath Integrated Pathology, Inc.,
Pittsburgh, PA). KRAS oncogene alterations were exam-
ined in codons 12 and 13. The microsatellite markers
assessed the presence of allelic imbalance, as measured by
loss of heterozygosity (LOH), at 10 genomic loci linked to
tumor suppressor genes associated with pancreaticobiliary
cancer. These genomic loci (genes) included: 1p (CMM1,
Lmyc), 3p (VHL, OGG1), 5q (MCC, APC), 9p (CDKN2A,
CDKN2B), 10q (PTEN, MXI1), 17p (TP53), 17q (NME1,
RNF34), 18q (DCC), 21q (TFF1, PSEN2), and 22q (NF2).
Quantitative allelic imbalance (LOH) and KRAS point
mutations were determined by PCR and subsequent ca-
pillary gel electrophoresis (ABI Genetic Analyzer) [23].
For LOH analysis, the normal allelic balance range was
determined to be two standard deviations from the aver-
age allelic ratio in which the fluorescence derived from the
shorter allele copy is divided by that of the longer allele
copy [33]. The presence of LOH was determined by those
allelic ratios that fell outside the thresholds. KRAS point
mutations were established by dideoxy chain termination.
Approximations of mutated versus non-mutated (non-
neoplastic) DNA for each sample were created by the ratio
of wild-type nucleotide and mutant nucleotide peak
heights. The mutational profile of microdissected cytologyslides and supernatants was characterized as positive for
malignancy based on the presence of at least one mutation
in any of the 16 LOH or KRAS markers.
KRAS point mutation analysis was based on dideoxy
chain termination (Sanger) sequencing (Applied Biosys-
tems, Grand Island, NY) with a threshold of detection of
8% mutation admixed with 92% wild type DNA. Loss of
heterozygosity analysis for detection of genomic deletion
was based on fragment analysis using fluorescent labeled
PCR primers (Applied Biosystems). Threshold for detec-
tion of LOH was 30% mutant DNA admixed with 70%
non-mutated DNA for an individual LOH marker. Al-
lelic dropout, a potential technical artifact related to low
levels or poor quality (degraded) DNA, was rigorously
controlled for by replicate analysis (minimum triplicate)
confirming the fidelity of all detectable mutations. Mo-
lecular analyses were performed by laboratory personnel
blinded to clinical and management features as well as
any prior molecular analysis on an individual patient.
Results
Between August 2011 and May 2012, 39 patients had pan-
creaticobiliary masses identified by cross-sectional imaging
and underwent FNA or biliary brushings. 9/39 patients
did not have appropriate follow up information available;
therefore, 30 patients were included in the final analysis.
Of these 30 patients, 23 underwent FNA and 7 underwent
biliary brushing to obtain specimens for cytological and
mutational profiling analyses. 21 patients were categorized
as having “aggressive” disease, and 9 patients were catego-
rized as having “non-aggressive” disease at the end of the
study. In total, 10/30 patients underwent surgery; surgical
pathology revealed that 5/10 had adenocarcinoma, 1/10
had intraductal tubulo-papillary neoplasm, and 4/10 had
IPMN.
Out of 30 patients, 21 specimens had sufficient cells for
cytology diagnosis. Of the 21 cytology specimens with suf-
ficient cellularity, 12 were negative, 5 were atypical, and 4
were positive for aggressive disease. Importantly, 30% of
the cytology specimens had either low cellularity (8/30) or
a non-diagnostic level of cells (1/30). All 9 specimens were
atypical, negative, or indeterminate for aggressive disease;
none were positive for malignancy by cytologic diagnosis
(Table 1).
Table 2 described the disease outcomes of patients com-
pared with the cytology results. 9/30 patients had non-
aggressive disease. Of these 9 patients, 7 had correspond-
ing negative cytology diagnoses, 1 had an indeterminate
cytology diagnosis and 1 had an atypical cytology diagno-
sis. 21/30 patients had aggressive disease. Of these 21 pa-
tients, 12 had corresponding positive or atypical cytology
(Table 2); 4 of these atypical diagnoses were made from a
sample that had low cellularity (Table 1). The remaining 9
patients with aggressive disease had corresponding falsely
Table 1 Comparison of cytology diagnoses with degrees of cellularity present in each FNA specimen
Degree of cellularity Cytology diagnosis (n = 30) Total
Negative Atypical Positive Indeterminate
Sufficient 12 5 4 0 21
Low 4 4 0 0 8
Non-diagnostic level 0 0 0 1 1
Total 16 9 4 1 30
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negative cytology had low cellularity (1/4 in Table 1), while
the remaining 8/9 patients had sufficient cellularity for a
cytology diagnosis (8/12 in Table 1).
26 patients categorized with a cytology diagnosis of
atypical, negative or indeterminate were analyzed by mu-
tational profiling. In 16/26 patients, the supernatant
underwent mutational profiling. For 9/26 patients, mi-
crodissected cytology slides were tested. And for 1 patient,
both the supernatant and microdissected slide were ana-
lyzed for mutations. All 26 patients had sufficient quantity
and quality of DNA required for mutational profiling.
KRAS and loss of heterozygosity (LOH) mutations were
examined, and 6/17 patients with aggressive disease were
positive for KRAS mutation. The inclusion of LOH muta-
tions correctly identified an additional 2 cases of aggres-
sive disease for a total of 8/17 cases of aggressive disease
identified by mutational profiling. Table 3 describes the
presence (positive) or absence (negative) of detectable mu-
tations in microdissected cytology slides or supernatants
from patients with non-aggressive disease or aggressive
disease with the corresponding cytology diagnoses indi-
cated. For patients with non-aggressive disease, 2 patients,
including 1 with atypical and 1 with indeterminate cy-
tology diagnosis, were correctly diagnosed by mutational
profiling. All 7 patients with negative cytology were nega-
tive by mutational profiling. For patients with aggressive
disease, diagnosis by mutational profiling was positive in
7/8 patients with atypical cytology and 1/9 patients with
falsely negative cytology. Therefore, mutational profiling
was able to provide additional information regarding the
presence of aggressive disease in 8/17 patients with either




Patient outcomes (n = 30) Total
Non-aggressive disease Aggressive disease
Negative 7 9 16
Atypical 1 8 9
Positive 0 4 4
Indeterminate 1 0 1
Total 9 21 30In our sample of patients, cytology alone detected only
20% (4/21) of aggressive disease with absolute certainty
(positive) (Table 2). However, when malignant (positive) cy-
tology testing and the results of mutational profiling on
negative, atypical or indeterminate cytology specimens were
analyzed together, 57% (12/21) of aggressive cases were
detected (Table 4). This increased detection was without a
compromise in the ability to conduct first line testing,
given that mutational analysis can be performed on dis-
carded or archivable cytology material. The diagnostic
yield of specimens was also increased by using the com-
bination of cytology and mutational profiling (100%, 30/30
Table 4) versus cytology alone (97%, 29/30 Table 2). When
added to first line cytology testing, mutational profil-
ing of specimens that were atypical, negative, or indeter-
minate by cytology increased the detection of aggressive
disease and the diagnostic yield of specimens regardless
of cellularity.
Discussion
Standard morphologic evaluation of FNA and biliary
brushing specimens carries a high false negative rate and
at times lacks diagnoses of pancreatic masses and their
associated biliary strictures [4-7,34]. This is largely due
to sampling variability resulting from FNA and biliary
brushing procedures, insufficient amount of cells avail-
able within resulting specimens, and difficulty in charac-
terizing cellular atypia in specimens. Our study aimed to
better understand the added value of second line muta-
tional profiling when used in conjunction with first line
cytology testing to detect aggressive disease when cytology
results were inconclusive for the presence of malignancy
(i.e. negative, indeterminate or atypical).
The panel of markers used in the mutational profiling
for this study was selected based on substantial evidence
supporting their involvement in pancreaticobiliary can-
cers. KRAS point mutation has been long-established as
a feature of pancreatic cancer [16,35]. Since the presence
of LOH is considered a worrisome feature in pancreatic
cysts [10,22,36], LOH is an additional logical candidate
for mutational profiling of pancreaticobiliary masses. The
panel used in this study examined LOH at 10 genomic loci
that have been linked to pancreaticobiliary cancer in
previous reports [37-39]. Using a combination of these
important mutational features, we were able to detect





Patient outcome (n = 26)
Non-aggressive disease Aggressive disease
Cytology diagnosis Cytology diagnosis
Atypical Negative Indeterminate Atypical Negative Indeterminate
Negative 1 7 1 1 8 0
Positive 0 0 0 7 1 0
Non-diagnostic 0 0 0 0 0 0
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by cytology alone in pancreatic masses and their associ-
ated biliary strictures.
As reported by others and supported by our study,
specimens positive for malignant disease via cytological
analysis are very likely to be associated with aggressive
disease given the high specificity (95-100%) of cytology
for malignancy [40,41]. However, given the poor sensitivity
of cytology for detecting aggressive/malignant disease, use
of mutational profiling in diagnosing patients was able to
detect aggressive disease in an additional 47% (8/17) of
the patients, including 1 patient with falsely negative cy-
tology results and 7 patients with atypical cytology results.
In addition, no patients with non-aggressive disease had
positive results by mutational profiling. Therefore, muta-
tional profiling has the potential to improve diagnostic
sensitivity for aggressive disease without compromise to
specificity when used as a supplement to first line cytology
testing. Such characteristics are of particular utility in
cases of low or non-diagnostic cellularity and uncertain
cytology diagnoses (i.e. negative, atypical, indeterminate).
Pauci- and acellular specimens can fail to provide suf-
ficient material for cytology as well as cell-based DNA
mutational profiling. In these cases, testing of super-
natant fluid provides an attractive alternative. Mutational
profiling of supernatants may contain higher quality and
quantity of DNA and detect more mutations associated
with malignancy and in some cases be more representa-
tive of the tumor [22] than cytology specimens [24-32].
Our study reinforces the added value of mutational profil-
ing in detecting aggressive disease in both cytology speci-
mens and normally discarded supernatant specimens,Table 4 Comparison of patient outcomes with combined
use of malignant (positive) cytology and mutational
profiling





(Cytology & mutational profiling)
Negative 9 9
Positive 0 12
Non-diagnostic 0 0with supernatants providing a source of DNA that does
not compete with those required by cytology. Mutational
profiling of both specimen types can provide additional
diagnostic information concerning the presence of aggres-
sive disease, especially when cytology is non-diagnostic/
indeterminate or negative, thus, enhancing the early
detection of malignancy in patients.
Our study has limitations, including a small sample
size that limits our ability to calculate the diagnostic per-
formance of mutational profiling in pancreatic masses
and associated biliary strictures. Although mutational
profiling allowed us to detect additional cases of aggres-
sive disease, even when cytology and mutational profiling
results were combined into one overall diagnosis, 9 cases of
malignancy were missed. These falsely negative results are
likely due to a combination of the less than perfect sensitiv-
ity of both tests as well as to sampling limitations related
to FNA and brushing techniques. Despite such limitations,
these promising results do provide support for future
larger scale studies, with the addition of supernatant ana-
lysis providing an opportunity to overcome some of these
limitations.
Conclusion
This study shows that a second line diagnostic test that
uses archivable cytology slides and normally discarded
supernatant specimens may enhance our ability to detect
pancreaticobiliary cancer; when first line cytology results
were uncertain (atypical), questionable (negative), or not
possible (non-diagnostic/indeterminate), mutational pro-
filing provided additional information regarding the
presence of aggressive disease. When used in conjunc-
tion with first line cytology testing, mutational profiling
increases the number of aggressive cases detected with-
out compromising the specificity associated with cy-
tology results. Using the generally discarded supernatant
fluid for analysis gives us the opportunity to perform
mutational profiling even when the specimen’s cellularity
is at a non-diagnostic level. The recognized presence of
false negative and indeterminate first line cytology test-
ing emphasizes the need for second line testing, such as
mutational profiling, to improve the early detection of
aggressive pancreaticobiliary disease.
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